Microbial Contamination Leads to Recall of Eye-Wash Solutions

News
Article

A customer complaint revealed microbial contamination issues affecting lots with expiration dates in late 2018 and early 2019.

FDA has posted news that Rugby Laboratories and Major Pharmaceuticals, through efforts with their distributor, United Exchange Corp. (Cerritos, Calif), are recalling lots of purified water-based products: Rugby eye irrigating solution and Major eye wash, due to microbial contamination issues. 

These problems, which could result in potentially sight-threatening eye infections for anyone using affected product, were brought to the attention of the manufacturers by a customer complaint. Both products were distributed throughout the US to wholesale and retail facilities, including hospitals and pharmacies. The companies are notifying distributors and customers of the recall by letter, and arranging for return of all recalled products. 

The recall affects Major EyeWash lot numbers G15905-G15912 and G16901-G16907, as well as G16910 and G16911, with expiration dates in October and November 2018, and January through March 2019.   Also affected are Rugby EyeWash lots G15908, 15909, 16904, 16908, 16912 and 16913, with expiration dates in October and November 2018 and January through March 2019.

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments